Sotatercept Improves Small Airway Disease and Hyperinflation in Patients with Pulmonary Hypertension.

ABSTRACT:

Rationale

Small airways disease (SAD) and hyperinflation are common in precapillary pulmonary hypertension (PH). Activin signaling plays an important role in airway and bronchial function.

Objective

To determine whether treatment with sotatercept, an activin signaling inhibitor, for severe precapillary PH is associated with improvements in physiologic markers of SAD and hyperinflation.

Methods

We conducted a single-center, retrospective cohort study of participants who received sotatercept for the treatment of severe precapillary PH despite background PH treatments who also had pulmonary function tests (PFT) before and after initiation of sotatercept treatment.

Measurements and main results

Forty-eight participants were included (median age 68 years, 77% female

SUBMITTER: Poor HD 

PROVIDER: S-EPMC12632688 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature